Physician profile
Daniela Whiteside
NPI 1134352867
$1,941.45
in general payments reported to CMS, 2019-2025
25 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $158 · 2021: $250 · 2022: $235 · 2023: $433 · 2024: $238 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $373.33 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $211.23 | 2020-2025 | Tryptyr, Eysuvis, Simbrinza |
| Horizon Therapeutics Plc | $198.76 | 2021-2023 | Tepezza |
| Astellas Pharma US INC | $145.82 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.49 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $128.31 | 2019-2023 | Acuvue |
| Aerie Pharmaceuticals, INC. | $117.93 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $92.52 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $72.48 | 2022 | |
| Notal Vision, INC. | $60.51 | 2024 | Foresee Home |
| Kala Pharmaceuticals, INC. | $59.20 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $53.98 | 2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $43.00 | 2021-2023 | |
| Allergan, INC. | $41.40 | 2021 | |
| Rxsight INC | $29.61 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $27.16 | 2023 | |
| Ani Pharmaceuticals, INC. | $24.57 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Maculogix, INC. | $18.84 | 2020 | |
| Abbvie INC. | $17.90 | 2024 | |
| Rayner Intraocular Lenses Limited | $17.41 | 2025 | Omidria |
| Novartis Pharmaceuticals Corporation | $16.54 | 2021 | |
| Oyster Point Pharma, INC. | $15.77 | 2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $12.67 | 2022 | |
| Lumenis, INC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Whiteside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.